Understanding the genetic and epigenetic drivers of AML
Comprehensive Informatic Analyses of AML Genomes and Epigenomes
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-11159516
This project uses large-scale DNA and epigenetic data to find which early mutations drive acute myeloid leukemia and point toward new targeted treatments for people with AML.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11159516 on ClinicalTrials.gov |
What this research studies
Researchers will analyze large genomic and epigenomic datasets from AML samples using new algorithms and statistical models to understand how initiating mutations in blood stem cells trigger leukemia. They will build computable models that translate complex mutation and methylation patterns into clear hypotheses about which molecular changes cause disease. Those hypotheses will help lab teams prioritize molecular targets for follow-up testing and potential drug development. The work combines bioinformatics, big-data methods, and collaboration with laboratory and clinical researchers to move findings toward therapies.
Who could benefit from this research
Good fit: Ideal candidates are people with a diagnosis of acute myeloid leukemia who can donate tumor samples or whose sequencing data can be shared for research.
Not a fit: People without AML or those whose leukemia is driven by mechanisms not captured by the datasets used may not see direct benefit from this project.
Why it matters
Potential benefit: Could reveal new, more precise molecular targets that lead to better and less toxic treatments for people with AML.
How similar studies have performed: Previous genomic studies have mapped AML mutations and led to targeted options for some subgroups, but this comprehensive informatics focus on initiating mutations and epigenetic mechanisms is relatively novel.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MILLER, CHRISTOPHER A — WASHINGTON UNIVERSITY
- Study coordinator: MILLER, CHRISTOPHER A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.